Dipartimento Ematologia, Oncologia e Medicina Molecolare, Istituto Superiore di Sanità, Viale Regina Elena 299, Roma, Italy.
Curr Opin Pharmacol. 2010 Aug;10(4):380-4. doi: 10.1016/j.coph.2010.05.002. Epub 2010 Jun 17.
Human cancer stem cells represent promising tools for new approaches to pathway-targeted drug discovery and preclinical screening. Because of their distinctive capability to recapitulate the development of the original tumors in vivo, the study of human cancer stem cells (CSCs) largely relies on models of xenograft transplantation into immunodeficient mice. In this frame, immunity and microenvironment-related issues need careful consideration. Here we shortly revise present knowledge on xenograft-related aspects of human CSCs studies.
人类肿瘤干细胞为新的靶向药物发现和临床前筛选途径提供了有前途的工具。由于其独特的能力，能够在体内重现原始肿瘤的发展，因此人类肿瘤干细胞（CSC）的研究在很大程度上依赖于异种移植到免疫缺陷小鼠中的模型。在这种情况下，需要仔细考虑免疫和微环境相关的问题。在这里，我们简要回顾了有关异种移植相关人类 CSC 研究的现有知识。
